Human Serum Paraoxonase 1 Decreases Macrophage Cholesterol Biosynthesis
- 1 March 2003
- journal article
- research article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 23 (3) , 461-467
- https://doi.org/10.1161/01.atv.0000060462.35946.b3
Abstract
Objective— Human serum paraoxonase 1 (PON1) activity is inversely related to the risk of developing an atherosclerotic lesion, which contains cholesterol-loaded macrophage foam cells. To assess a possible mechanism for this relationship, we analyzed the effect of PON1 on cellular cholesterol biosynthesis. Methods and Results— Mouse peritoneal macrophages (MPMs) were harvested from PON1-deficient mice (PON1° and PON1°/E° mice on the genetic background of C57BL/6J and E° mice, respectively). PON1°/E° mice exhibited a significantly 51% increased atherosclerotic lesion area and 35% increased macrophage cholesterol content compared with control E° mice. In parallel, macrophage cholesterol biosynthesis rates were increased in PON1-deficient mice MPMs by 50% compared with their controls. Incubation of macrophages with human PON1 revealed a dose-dependent inhibitory effect (up to 84%) on macrophage cholesterol biosynthesis. We demonstrated a PON1 phospholipase-A 2 –like activity on MPMs, evidenced by release of polyunsaturated fatty acids and formation of lysophosphatidylcholine. On incubation of macrophages with lysophosphatidylcholine, a dose-dependent inhibition (up to 40%) of cellular cholesterol biosynthesis was noted. The inhibitory effect of PON1 on macrophage cholesterol biosynthesis was shown to be downstream to mevalonate, probably at the lanosterol metabolic point. Conclusions— PON1 inhibits macrophage cholesterol biosynthesis and atherogenesis probably through its phospholipase-A 2 –like activity.Keywords
This publication has 33 references indexed in Scilit:
- Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout miceFree Radical Biology & Medicine, 2003
- Macrophage Foam Cell Formation with Native Low Density LipoproteinJournal of Biological Chemistry, 2002
- Angiotensin II Reduces Macrophage Cholesterol Efflux: A Role for the AT-1 Receptor but Not for the ABC1 TransporterBiochemical and Biophysical Research Communications, 2002
- Enzymatically Active Paraoxonase-1 Is Located at the External Membrane of Producing Cells and Released by a High Affinity, Saturable, Desorption MechanismJournal of Biological Chemistry, 2002
- Multiple Substrates for Paraoxonase-1 during Oxidation of Phosphatidylcholine by PeroxynitriteBiochemical and Biophysical Research Communications, 2002
- Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy- 3-methylglutaryl coenzyme A reductase inhibitor11CRESTOR is a trademark, the property of AstraZeneca PLC. Research discussed in this article was supported by AstraZeneca.The American Journal of Cardiology, 2001
- Macrophage Foam Cell Formation During Early Atherogenesis Is Determined by the Balance Between Pro-Oxidants and Anti-Oxidants in Arterial Cells and Blood LipoproteinsAntioxidants and Redox Signaling, 1999
- Lyso-PAF Analogues and Lysophosphatidylcholines from the Marine Sponge Spirastrella abata as Inhibitors of Cholesterol BiosynthesisJournal of Natural Products, 1999
- Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cellsPublished by Elsevier ,1992
- Beyond CholesterolNew England Journal of Medicine, 1989